IMNM heads into the final week of September with shorts rebuilding, options sentiment flipping sharply negative, and the stock down 15% on the week to $21.89, all while a unanimous analyst buy consensus sits 65% above the current price.
The most striking shift this week is in options positioning, where the market has moved meaningfully more defensive. The put/call ratio has climbed to 0.55, more than double its 20-day average of 0.26 and 2.6 standard deviations above the mean, placing it near the highest defensive reading of the past year (52-week high of 0.89). As recently as mid-September, the PCR was running below 0.20. The reversal has been swift: the ratio more than doubled between September 21 and September 29, tracking closely with the stock's 15% weekly decline.
Short positioning has tightened alongside the price move. Short interest has risen 7.8% over the week to 18.0% of the free float, a level that ranks in only the 10th percentile of the short score universe, meaning the short setup is more charged than 90% of the market. The ORTEX short score is running at 71.6, up from around 69.5 a week ago, reinforcing the picture of growing bearish conviction in the stock. The lending market itself is not adding pressure: borrow availability is ample at 347%, meaning there is roughly three-and-a-half times as much stock available to lend as is currently shorted, and the cost to borrow is barely above half a percent annually. Shorts face no meaningful squeeze mechanics at these levels.
The Street remains firmly bullish, but that consensus is increasingly a valuation call rather than a near-term trading signal. All 12 analysts covering IMNM rate it a buy, with a mean price target of $36, implying 64% upside from current levels. Alliance Global Partners initiated coverage on September 21 with a Buy and a $32 target, making it the most recent addition to an already unanimous register. The bull case centres on varegacestat, where positive Phase 3 RINGSIDE results in desmoid tumors and an April 2027 PDUFA support a potential U.S. launch, alongside a multi-asset ADC pipeline including IM-1021, IM-3050, and IM-1617, with initial lymphoma data expected in the second half of 2026. Bears counter that most of that pipeline is still in Phase 1 or earlier, that the ROR1 target thesis remains scientifically contested, and that the company's $520 million cash balance, while extending runway into 2028, does not offset the execution concentration risk around a single late-stage asset. The analyst recommendation differential factor score ranks in the 97th percentile, reflecting how one-sided the formal coverage remains, even as the stock trades well below the cluster of targets.
Ownership data carries a few points worth watching. T. Rowe Price is the largest institutional holder at roughly 19% of shares, and its 13G filing from August shows the position has grown. Fidelity (FMR LLC) holds a further 15%. Immunome Aggregator LP and Enavate Sciences GP are both on the 13D register, meaning active investors with disclosed influence over the company's direction hold stakes at or near the 5% threshold; as with all 13D/G positions, these are as-last-disclosed and holders can fall below 5% without filing again. On the insider side, the net 90-day flow is negative: the CSO sold $334,000 worth of shares on September 11 under a pre-arranged 10b5-1 plan, following a cluster of director-level 10b5-1 sales in August. All of the recent insider selling has been plan-driven, which reduces its signal value as a directional indicator.
Earnings are not due until November 9, roughly 40 days away. The last four prints have produced mixed reactions: a one-day gain of nearly 9% in August 2026, followed by declines of 4%, 2.4%, and 3.5% on the other three occasions. Wikipedia attention for IMNM has spiked well above its own 90-day history, with a z-score of 5.1 recorded on September 22, suggesting the retail attention behind this week's price move has been unusually concentrated. Peers have broadly shared the weakness: CRVS, SANA, and NBP are each down 12% to 14% on the week, while SLDB has fallen nearly 20%, suggesting sector-wide pressure rather than a company-specific catalyst driving IMNM's move.
The key watch over the next six weeks is whether the growing put/call ratio and rebuilding short interest stabilise or intensify ahead of the November 9 earnings date, and whether any of the pipeline readouts, particularly the initial lymphoma data expected in the second half of 2026, land before the print to shift the narrative.
See the live data behind this article on ORTEX.
Open IMNM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
